慢性髓细胞白血病不同临床缓解状态下的T细胞亚群特点研究
|
摘要
目的探讨不同临床缓解状态下慢性髓细胞白血病(CML)患者T细胞亚群特点。方法 104例CML患者分为未缓解组(n=24),细胞遗传学缓解(CCyR)组(n=13),主要分子生物学缓解4. 5(MR4. 5)组(n=67),流式检测外周血CD8+T及CD4+T亚群Th1、Th2、Treg。结果未缓解组、CCyR组、MR4. 5组分别有62. 50%、15. 38%及15. 15%的患者Th1低于正常下限。未缓解组Th1降低率高于CCyR组及MR4. 5组,Th1平均值低于CCyR组及MR4. 5组(P <0. 05)。Treg、Th2及CD8+T三组间差异无统计学意义(P> 0. 05)。结论 CML患者良好的临床缓解状态表现出较高的Th1水平。
Objective To investigates the T cell subtypes of patients with chronic myeloid leukemia( CML) in different clinical remission situations.Methods One hundred and four CML patients at chronic-phase were divided into unremission group( n =24),complete cytogenetic response( CCyR) group( n = 13),and molecular response4. 5( MR4. 5) group( n = 67).The peripheral blood of the patients was collected and analyzed by flow-cytometry for levels of CD8+T and CD4+T cell subtypes as well as Th1,Th2 and Treg.Results Th1 level below the low limit of normal was found in 62. 50% of the patients in the unremission group,15. 38% in the CCyR group and 15. 15% in the MR4. 5 group,respectively. The percentage of low-Th1 patients in the unremission group was significantly higher than that in the CCyR group and the MR4. 5 group( P < 0. 05).For the comparison of Treg,there was no statistically significant difference in Th2 and CD8+T proportions among the three groups( P > 0. 05).Conclusion The better clinical remission situations of CML patients show a higher Th1 level.
Objective To investigates the T cell subtypes of patients with chronic myeloid leukemia( CML) in different clinical remission situations.Methods One hundred and four CML patients at chronic-phase were divided into unremission group( n =24),complete cytogenetic response( CCyR) group( n = 13),and molecular response4. 5( MR4. 5) group( n = 67).The peripheral blood of the patients was collected and analyzed by flow-cytometry for levels of CD8+T and CD4+T cell subtypes as well as Th1,Th2 and Treg.Results Th1 level below the low limit of normal was found in 62. 50% of the patients in the unremission group,15. 38% in the CCyR group and 15. 15% in the MR4. 5 group,respectively. The percentage of low-Th1 patients in the unremission group was significantly higher than that in the CCyR group and the MR4. 5 group( P < 0. 05).For the comparison of Treg,there was no statistically significant difference in Th2 and CD8+T proportions among the three groups( P > 0. 05).Conclusion The better clinical remission situations of CML patients show a higher Th1 level.
引文
[1]Sacha T,Saglio G.Nilotinib in the treatment of chronic myeloid leukemia[J].Future Oncol,2018,Epub ahead of print.
[2]Hochhaus A,Larson RA,Guilhot F,et al.Long-term outcomes of imatinib treatment for chronic myeloid leukemia[J]. N Engl J Med,2017,376(10):917-927.
[3]Cortes JE,Saglio G,Kantarjian HM,et al.Final 5-year study results of DASISION:the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial[J]. J Clin Oncol,2016,34(20):2333-2340.
[4]Bhatia R.Novel approaches to therapy in CML[J].Hematology Am Soc Hematol Educ Program,2017,2017(1):115-120.
[5]Jabbour EJ,Hughes TP,Cortes JE,et al.Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia[J].Leuk Lymphoma,2014,55(7):1451-1462.
[6] Annunziato F,Romagnani C,Romagnani S. The 3 major types of innate and adaptive cell-mediated effector immunity[J]. J Allergy Clin Immunol,2015,135(3):626-635.
[7]Gagliani N,Huber S. Basic aspects of T helper cell differentiation[J].Methods Mol Biol,2017,1514:19-30.
[8]Piccioni M,Chen Z,Tsun A,et al. Regulatory T-cell differentiation and their function in immune regulation[J]. Adv Exp Med Biol,2014,841:67-97.
[9]Chen P,Wang M,Li D,et al.The alteration and clinical significance of Th22/Th17/Th1 cells in patients with chronic myeloid leukemia[J].J Immunol Res,2015,2015:416123.
[2]Hochhaus A,Larson RA,Guilhot F,et al.Long-term outcomes of imatinib treatment for chronic myeloid leukemia[J]. N Engl J Med,2017,376(10):917-927.
[3]Cortes JE,Saglio G,Kantarjian HM,et al.Final 5-year study results of DASISION:the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial[J]. J Clin Oncol,2016,34(20):2333-2340.
[4]Bhatia R.Novel approaches to therapy in CML[J].Hematology Am Soc Hematol Educ Program,2017,2017(1):115-120.
[5]Jabbour EJ,Hughes TP,Cortes JE,et al.Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia[J].Leuk Lymphoma,2014,55(7):1451-1462.
[6] Annunziato F,Romagnani C,Romagnani S. The 3 major types of innate and adaptive cell-mediated effector immunity[J]. J Allergy Clin Immunol,2015,135(3):626-635.
[7]Gagliani N,Huber S. Basic aspects of T helper cell differentiation[J].Methods Mol Biol,2017,1514:19-30.
[8]Piccioni M,Chen Z,Tsun A,et al. Regulatory T-cell differentiation and their function in immune regulation[J]. Adv Exp Med Biol,2014,841:67-97.
[9]Chen P,Wang M,Li D,et al.The alteration and clinical significance of Th22/Th17/Th1 cells in patients with chronic myeloid leukemia[J].J Immunol Res,2015,2015:416123.